glp-1 cardiovascular outcomes 2025 news An Observational Study of of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists Alarming rise in weight loss

BMJ (2023)

Confirmatory large-scale trials are essential to ascertain the potential efficacy of GLP-1RAs in specifically improving the stroke outcomes

Signs of an allergic reaction include severe itching or rash, hives, difficulty breathing or swallowing, lightheadedness, facial flushing, nausea, vomiting, heart palpitations, and swelling of the face, eyes, tongue, or throat

Tirzepatide sits between the two for side-effect intensity but lacks the glucagon-driven hepatic and energy-expenditure effects that make retatrutide attractive in the first place

Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): results from a first-in-human phase I study

Research has extensively explored the effects of endogenous and exogenous GLP-1 on brain activity related to homeostasis and reward systems, particularly in the context of obesity and type 2 diabetes mellitus (T2DM)